US FDA Rare Pediatric Disease Designation in Rett syndrome
Filed with ASX · · 2 pages · English
Neurotech International Ltd. on 6ix
Story so far
Earlier from Neurotech International
- Appendix 4E & Annual Report to shareholders
- Positive Human PK Study Results for NTI164
- NTI164 Preclinical Toxicology Studies Update
- Appendix 4D and Half Year Accounts
- Positive Opinion on OMPD for NTI164 in Europe
Later from Neurotech International
- Neurotech receives $4.73m R&D Tax Incentive Refund
- Trading Halt
- Binding Commitments Received for a $4 Million Placement
- Quarterly Activities/Appendix 4C Cash Flow Report
- Approval received for NTI164 Phase 3 Clinical Study in ASD
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International